Using multivariate regression (Table 3), log10 of plasma amylin as an outcome remained to be negatively associated with duration of diabetes (β = −0.18, SE=0.06, p=0.002) and insulin treatment (β= −0.49, SE=0.19, p=0.03) after adjusting for diabetes, age, gender, ethnicity, education, ApoE4, BMI, cardiovascular disease, stroke, creatinine, the lipid profile including cholesterol, LDL and HDL and diabetic medications. Here, INS is linked to stroke disorder.